Liquid biopsies that detect circulating tumour DNA (ctDNA) have the potential to revolutionise the personalised management of colorectal cancer. For patients with early-stage disease, emerging clinical applications include the assessment of molecular residual disease after surgery, the monitoring of adjuvant chemotherapy efficacy, and early detection of recurrence during surveillance. In the advanced disease setting, data highlight the potential of ctDNA levels as a prognostic marker and as an early indicator of treatment response. ctDNA assessment can complement standard tissue-based testing for molecular characterisation, with the added ability to monitor emerging mutations under the selective pressure of targeted therapy. Here we provide an overview of the evidence supporting the use of ctDNA in colorectal cancer, the studies underway to address some of the outstanding questions, and the barriers to widespread clinical uptake.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S2468-1253(23)00146-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dementia Care Practice.
Alzheimers Dement
December 2024
University of Florida, Gainesville, FL, USA.
Introduction: Colonoscopies are medical procedures used to identify colon abnormalities and remove polyps to decrease the incidence of colorectal cancer. Prior to this exam, patients must undergo bowel preparation to ensure proper cleansing of the colon and maximize outcomes (e.g.
View Article and Find Full Text PDFLife after Pelvic Exenteration for Rectal Cancer: The Patient and Carer Perspective on Long Term Consequences and Survivorship.
Ann Surg
January 2025
Surgical Outcomes Research Centre (SOuRCe), Royal Prince Alfred Hospital, Sydney, Australia.
Objective: To explore the perspectives and experiences of patients and carers living with the long-term consequences of pelvic exenteration.
Summary Background Data: Pelvic exenteration is accepted as the standard of care for selected patients with locally advanced or recurrent rectal cancer. With contemporary 5-year survival reported at 40-60%, the number of long-term survivors is expected to increase.
Marine-Derived Compound Targeting mTOR and FGFR-2: A Promising Strategy for Breast, Lung, and Colorectal Cancer Therapy.
Med Chem
January 2025
Integrated Genetics and Molecular Oncology Group, Department of Genetic Engineering, College of Engineering and Technology, SRM Institute of Science and Technology, Kattankulathur, Chennai, Tamilnadu, 603203, India.
Introduction: The marine habitat is a plentiful source of diverse, active compounds that are extensively utilised for their medicinal properties. Pharmaceutical trends have currently changed towards utilising a diverse range of goods derived from the marine environment.
Method: This study aimed to examine the inhibitory effects of bioactive chemicals derived from marine algae and bacteria.
Prognostic Value of Tumor Regression Grade Combined with Pathological Lymph Node Status in Initially Node-Positive Rectal Cancer Treated with Neoadjuvant Chemoradiotherapy.
J Invest Surg
January 2025
Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Background: The prognostic value of tumor regression grade (TRG) after neoadjuvant chemoradiotherapy for rectal cancer is inconsistent in the literature. Both TRG and post-therapy lymph node (ypN) status could reflect the efficacy of neoadjuvant therapy. Here, we explored whether TRG combined with ypN status could be a prognostic factor for MRI-based lymph node-positive (cN+) rectal cancer following neoadjuvant chemoradiotherapy.
View Article and Find Full Text PDFColorectal Cancer and Its Microenvironment: A Brief Review.
Med J Islam Repub Iran
September 2024
Department of Oncology, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan.
Background: The narrative review aims to explore CRC pathogenesis by deciphering genetic-environmental interactions, analyzing the tumor microenvironment's role, and assessing treatment responses. These objectives seek to enhance clinical decision-making and improve CRC patient care through a comprehensive understanding of the disease.
Methods: A narrative review from 2019 to 2024 on colorectal cancer (CRC) pathogenesis and treatment strategies was conducted.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!